 |
|
|
Table 1. Paclitaxel/Platinum Combinations Versus Comparator Arms in Trials
|
Trial
|
Treatment Regimens
|
No. of Patients
|
% Early Crossover
|
Progression-free Survival (mo)
|
Overall Survival (mo)
|
|
GOG-132
|
Paclitaxel (135 mg/m2, 24 h) and cisplatin (75 mg/m2) |
201 |
22% |
14.2 |
26.6 |
| Cisplatin (100 mg/m2) |
200 |
40% |
16.4 |
30.2 |
| Paclitaxel (200 mg/m2, 24 h) |
213 |
23% |
11.2ª |
26 |
|
MRC-ICON3
|
Paclitaxel (175 mg/m2, 3 h) and carboplatin AUC 6 |
478 |
23% |
17.3 |
36.1 |
| Carboplatin AUC 6 |
943 |
25% |
16.1 |
35.4 |
| Paclitaxel (175 mg/m2, 3 h) and carboplatin AUC 6 |
232 |
23% |
17 |
40 |
| Cyclophosphamide (750 mg/m2) and doxorubicin (75 mg/m2) and cisplatin (75 mg/m2) |
421 |
20% |
17 |
40 |
|
GOG-111[19] |
Paclitaxel (135 mg/m2, 24 h) and cisplatin (75 mg/m2) |
184 |
None |
18 |
38 |
| Cyclophosphamide (750 mg/m2) and cisplatin (75 mg/m2) |
202 |
None |
13ª |
24ª |
|
OV-10[20] |
Paclitaxel (175 mg/m2, 3 h) and cisplatin (75 mg/m2) |
162 |
None |
15.5 |
35.6 |
| Cyclophosphamide (750 mg/m2) and cisplatin (75 mg/m2) |
161 |
4% |
11.5ª |
25.8ª |
|
AUC = area under the curve; h = hour; mo = month.
|
|
ªStatistically inferior result (P < .001–< .05).
|
References
-
du Bois A, Lück HJ, Meier W, et al.: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (17): 1320-9, 2003.
[PUBMED Abstract]
-
Neijt JP, Engelholm SA, Tuxen MK, et al.: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18 (17): 3084-92, 2000.
[PUBMED Abstract]
|
|
|
